PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Do animals fall for optical illusions? What fish and birds can teach us about perception

2025-10-20
(Press-News.org) Have you ever looked at two circles of exactly the same size and sworn one was larger? If so, your eyes have been tricked by the Ebbinghaus illusion, a classic example of how context can shape what we see. Place a circle among other smaller circles, and it seems bigger; place it among larger ones, and it shrinks before our eyes. This illusion fascinates psychologists because it reveals that perception is not a mirror of the outside world but a clever construction of the brain.

But here is the question that inspired our study: do other animals fall for the same tricks? If a tiny fish or a bird perceives the illusion, what does that tell us about the way they see and interpret their surroundings?

Illusions are more than curiosities. They are powerful tools to understand how brains assemble sensory information. When perception goes ‘wrong’, it highlights the shortcuts and strategies the brain uses to make sense of complex environments.

In humans, the Ebbinghaus illusion is linked to global processing: the tendency to interpret a scene as a whole before focusing on details. But not all animals live in the same sensory world we do. By testing illusions across species, we can ask whether shared patterns point to deep evolutionary roots, or whether differences reveal adaptations to particular ecological niches. For example, global processing may have evolved in species that need to rapidly integrate complex scenes—such as detecting predators or evaluating group size—while local processing may be favored in species that rely on precise object recognition, like picking out seeds or prey items against a cluttered background.

Fish versus birds: two worlds of vision

To explore this, we turned to two very different species: the guppy (Poecilia reticulata) and the ring dove (Streptopelia risoria).

Guppies inhabit shallow tropical streams full of flickering light, dense vegetation, and unpredictable predators. Their survival depends on rapid decisions: choosing mates, joining shoals, and escaping threats. In such a cluttered world, being able to judge relative size at a glance can be crucial.

Ring doves, by contrast, are terrestrial granivores. They spend much of their time pecking at small seeds scattered on the ground. Precision and attention to fine detail could matter more than analyzing the whole scene. Moreover, their binocular vision allows them to make accurate judgments of distance and size in a very different context.

By placing these species side by side, we asked: does the same illusion deceive both a fish darting through water and a bird searching the ground?

Circles of deception

Our experiments used food as the central ‘circle’. For guppies, flakes of food were placed within arrays of smaller or larger surrounding circles. For doves, millet seeds were presented in similar arrangements.

The results were striking: Guppies consistently fell for the illusion. When food was surrounded by smaller circles, the guppies chose it more often, as if it really was larger. Their perception closely mirrored that of humans. Ring doves, however, told a different story. At the group level, they showed no clear susceptibility to the illusion. Some individuals behaved as humans did, others in the opposite way, and many seemed unaffected altogether. This variability suggests that doves may rely on different perceptual strategies; more local, detail-oriented, and less swayed by surrounding context.

Why does it matter?

At first glance, it might seem like just an amusing trick of vision. But these findings speak to deeper questions in evolutionary biology and comparative cognition: perception is not about accuracy for its own sake, it is about what works in a given environment. For guppies, integrating the whole scene may help them navigate visually complex streams, spot larger mates, or quickly gauge relative sizes in a shoal. For doves, tuned to picking out seeds against a messy background, focusing on absolute size and local details may perhaps be more helpful.

The study also reminds us that variation within a species can be as revealing as differences between species. The doves’ mixed responses suggest that individual experience or innate bias can strongly shape how an animal interprets illusions. Just like in humans, where some people are strongly fooled by illusions and others hardly at all, animal perception is not uniform.

A window into other minds

By comparing species as different as fish and birds, we get a glimpse of the extraordinary diversity of perceptual worlds. The Ebbinghaus illusion is only one of many tools researchers use to explore these worlds, but it highlights a key point: what we see is not always what is there.

For humans, this is a reminder of the brain’s creative shortcuts. For animals, it shows how ecological pressures sculpt perception in ways that fit each species’ lifestyle. And for science, it opens a window onto the evolutionary origins of cognition itself. Studying illusions across species helps us understand not only how animals see but also how perception evolves to meet the challenges of life on Earth.

END


ELSE PRESS RELEASES FROM THIS DATE:

New guideline emphasizes conversations about mood, mental health between patients and clinicians

2025-10-20
Depression is a mental illness, and support for depression can improve emotions, thoughts, and well-being. A new guideline from the Canadian Task Force on Preventive Health Care recommends that patients aged 18 and older talk to their health care providers about depression rather than undergo routine screening with standard tools, like questionnaires. The guideline is published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250237. In Canada, depression is common, with about 1 in 10 people (without bipolar disorder) experiencing depression in their lifetimes. It negatively affects how a person ...

Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure

2025-10-20
Philadelphia, October 20, 2025 – Peanuts represent one of the most common causes of immunoglobulin E (IgE)-mediated, or anaphylactic, food allergies in children, yet a landmark study found that early introduction of peanut to infants may lower their risk of developing this allergy. Now, a new study from researchers from Children’s Hospital of Philadelphia (CHOP) has shown that the rates of diagnosis of peanut and other IgE-mediated food allergies have declined since the adoption of guidelines encouraging early introduction practices. The findings, published today ...

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

2025-10-19
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma In this trial, VT3989 demonstrated notable antitumor activity, with a disease control rate of 86% at the clinically optimized dosing levels These data provide the first clinical proof-of-concept for effectively drugging the Hippo-YAP-TEAD pathway VT3989 was awarded Orphan Drug Designation and Fast Track Designation for the treatment of mesothelioma by the FDA BERLIN, OCTOBER 19, 2025 ― The first-in-class YAP-TEAD inhibitor ...

Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer

2025-10-19
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found. The observation by researchers at the University of Florida and the University of Texas MD Anderson Cancer Center is a defining moment in a decade-plus of research testing mRNA-based therapeutics designed to “wake up” the immune system against cancer. Building on a previous UF study, the observation also marks a significant step toward a long-awaited universal cancer vaccine to ...

ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy

2025-10-19
Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after treatment as those who never received a vaccine These findings have prompted a randomized Phase III trial to determine if mRNA COVID vaccines should be part of the standard of care for this type of therapy If validated, findings could significantly increase the number of patients who benefit from immunotherapy BERLIN, OCTOBER 19, 2025 ― Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning ...

Drug combo cuts risk of death in advanced prostate cancer by 40%

2025-10-19
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination therapy, which adds a drug called enzalutamide to commonly prescribed hormone therapy, reduced deaths in patients with recurrent prostate cancer after surgery or radiation for whom other treatments are no longer an option. The trial results were published in The New England Journal of Medicine (NEJM) with simultaneous presentation during the European Society for Medical Oncology Congress (ESMO) Oct. 19 in Berlin. “After ...

ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors

2025-10-19
BERLIN October 19, 2025 – Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy. These findings, which stem from the ASCENT-03 trial in triple-negative breast cancer co-led by investigators at Dana-Farber Cancer Institute, are presented today at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. They are also published simultaneously in the New England Journal ...

Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer

2025-10-18
BERLIN October 18, 2025 – Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, are presented today by Dr. Erica Mayer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany. Tumors that express the estrogen receptor (ER) account for roughly 70% ...

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients

2025-10-18
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal paraganglia Study found belzutifan shrank tumors and improved symptoms without surgery Belzutifan is the first oral and only FDA-approved treatment for patients with advanced, inoperable, or metastatic PPGL FDA granted approval for treating PPGL in May 2025 based on these trial results BERLIN, OCTOBER 18, 2025 – A multicenter Phase II clinical ...

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients

2025-10-18
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression First head-to-head study comparing second-line treatments lenvatinib plus everolimus vs. cabozantinib Combination offers option for patients with metastatic clear-cell renal carcinoma (ccRCC) who experience disease progression following first-line immunotherapy BERLIN, OCTOBER 18, 2025 ― Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney ...

LAST 30 PRESS RELEASES:

Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer

Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer

What is the extent of disparities in cancer clinical trials among low- and middle-income countries?

Invisible poison: Airborne mercury from gold mining is contaminating African food crops, new study warns

Nearly half of Finns with chronic conditions find medication therapy a burden

Do animals fall for optical illusions? What fish and birds can teach us about perception

New guideline emphasizes conversations about mood, mental health between patients and clinicians

Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer

ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy

Drug combo cuts risk of death in advanced prostate cancer by 40%

ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors

Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients

New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease

Sylvester Cancer Tip Sheet for October 2025

Three science and technology leaders elected to Hertz Foundation Board of Directors

Jump Trading CSO Kevin Bowers elected to Hertz Foundation Board of Directors

Former Inscripta CEO Sri Kosaraju elected to Hertz Foundation Board of Directors

Citadel’s Jordan Chetty elected to Hertz Foundation Board of Directors

McGill research flags Montreal snow dump, inactive landfills as major methane polluters

A lightweight and rapid bidirectional search algorithm

Eighty-five years of big tree history available in one place for the first time

MIT invents human brain model with six major cell types to enable personalized disease research, drug discovery

Health and economic air quality co-benefits of stringent climate policies

How immune cells deliver their deadly cargo

How the brain becomes a better listener: How focus enhances sound processing

Processed fats found in margarines unlikely to affect heart health

[Press-News.org] Do animals fall for optical illusions? What fish and birds can teach us about perception